Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Update

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,420,000 shares, a drop of 5.5% from the December 15th total of 3,620,000 shares. Based on an average daily volume of 426,500 shares, the days-to-cover ratio is currently 8.0 days.

Ascendis Pharma A/S Trading Down 2.7 %

Ascendis Pharma A/S stock traded down $3.49 during midday trading on Friday, reaching $128.13. The stock had a trading volume of 359,329 shares, compared to its average volume of 307,398. The firm's 50-day moving average price is $133.13 and its 200 day moving average price is $133.48. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00.

Analysts Set New Price Targets

ASND has been the subject of several research analyst reports. Stifel Nicolaus boosted their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a "buy" rating in a research report on Friday, November 15th. StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Bank of America raised their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. Cantor Fitzgerald restated an "overweight" rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Finally, UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price on the stock. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Ascendis Pharma A/S presently has an average rating of "Moderate Buy" and a consensus target price of $192.07.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $30,000. GAMMA Investing LLC raised its holdings in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 214 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock worth $102,000 after purchasing an additional 80 shares in the last quarter. Pursue Wealth Partners LLC bought a new position in shares of Ascendis Pharma A/S in the third quarter worth approximately $217,000. Finally, Rhumbline Advisers raised its stake in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after purchasing an additional 143 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.